Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, is pleased to announce the appointment of Marvin Garovoy, M.D. as Chief Medical Officer. Dr. Garovoy is a transplant nephrologist, biotechnology executive and former university professor with experience in all stages of clinical development.
“While serving as Acting Chief Medical Officer since January 2012, Dr. Garovoy has helped Medgenics achieve a number of important clinical and corporate milestones,” stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. “Dr. Garovoy’s vast experience and skillset will be a considerable asset as we initiate several new clinical trials through the end of 2012 in the U.S. and Israel, and leverage our Biopump platform technology as we explore the expansion of our development portfolio into new indications.”
For the past 16 years Dr. Garovoy has been a biotechnology and pharmaceutical industry executive and consultant, having held a variety of positions including Chief Medical Officer at drug development companies working on biologics and small molecule drugs. He has led or been involved with the clinical development and U.S. Food and Drug Administration (FDA) submissions and approvals at a number of companies including Genentech, Inc., XOMA Corporation, Hyperion Therapeutics, Inc, Arriva Pharmaceuticals, Inc,, Peregrine Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. He was lead physician on the development of an anti-adhesion monoclonal antibody (Raptiva) in Phase I and Phase II clinical studies at XOMA and in collaboration with Genentech on Phase III clinical studies to FDA approval.
Dr. Garovoy has particular expertise in inflammatory and immunologically mediated diseases including nephrology (kidney transplantation), cardiovascular (heart transplantation), respiratory (asthma, lung transplantation), endocrinology (diabetes), gastrointestinal (inflammatory bowel disease), dermatology (psoriasis, atopic dermatitis), rheumatology (rheumatoid arthritis, systemic lupus) and metabolic diseases.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV